Application

MPLA PHAD^® has been used: as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccineas toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine

Biochem/physiol Actions

Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications. MPLA used in vaccination improves B cell and T cell-mediated immunity.

General description

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD^®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.

Legal Information

PHAD is a registered trademark of Avanti Polar Lipids, Inc.

Other Notes

For R&D use only. Not for drug, household, or other uses.

Packaging

2 mL Amber Glass Crimp Cap Vial (699800P-1mg)

2 mL Amber Glass Crimp Cap Vial (699800P-5mg)